US-based precision medicine technology developer Intervenn Biosciences has closed a $201m series C round co-led by telecoms firm SoftBank and health system Heritage Provider Network.
Irving Investors and Highside Capital Management also co-led the round, which was filled out by Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures.
Intervenn Biosciences has developed an artificial intelligence-equipped glycoproteomics platform and a liquid biopsy assay for immune checkpoint inhibitor response prediction. It will use the series C funding to accelerate technology development and commercialisation efforts.
Intervenn’s co-founders include faculty from two institutions – Stanford University’s Carolyn Bertozzi and University of California, Berkeley’s Carlito Lebrilla.
Aldo Carrascoso, co-founder and chief executive of Intervenn Biosciences, said: “We are thrilled to have such strong support from this global investor group to support the next phase of our evolution.
“Our new investors, as well as our existing investors, recognise the transformative potential of our technology and bring strong industry knowledge that will result in a positive partnership for Intervenn.
“With this fundraising, we believe Intervenn is ideally positioned to unlock the glycoproteome as a novel and fundamental layer in biology, which will reveal a myriad of new insights on how to diagnose and treat disease.”
Anzu Partners led a $34m series B round in November 2020, when Xeraya Capital, Oriza Ventures, the Ojjeh family and the Korenvaes family also invested.
Genoa Ventures led a $9.4m round in December 2018, with participation from True Ventures, Amplify Partners, Boost VC and Prado SV.
